1Andrea P,Noam Z,Julin L,et al.In vivo RNA interference-mediated ablation of MDR1 and P-glycoprotein[J].Clin Cancer Res,2005,15(6):4487-4494.
2Wright SR,Boag AH,Valdimarsson G,et al.Immunohistochemical detection of multidrug resistance protein in human lung cancer and normal lung[J].Clin Cancer Research,1998,4 (9):2279-2289.
3Kiyotaka Y,Genichivo I,Tomoyuki Y,et al.Breast cancer resistance protein impacts clinical outcome in platinum-based chemotherapy for advanced non-small cell lung cancer[J].Clin Cancer Res,2004,10(3):1691-1697.
4Bai F,Nakanishi Y,Kawasaki M,et al.Immunohistochemical expression of glutathione S-transferase-Pi can predict chemotherapy response in patients with non-small cell lung carcinoma[J].Cancer,1996,78(3):416.
6Mistry P,Stewart AJ,Dangerfield W,et al.In vitro and in vivo characterization of XR11576,a novel,orally active,dual inhibitor of topoisomerase Ⅰ and Ⅱ[J].Anticancer Drugs,2002,13 (1):15 -28.
7Lord RV,Brabender J,Gandara D,et al.Low ERCCI expression correlates with prolonged survival after cisplatin plus gemcitabine chemotherapy in non-small cell lung cancer[J].Clin Cancer Res,2002,8(7):2286 -2291.
8George R,Simon S,Sharma D,et al.ERCCI expression is a predictor of survival in resected patients with non-small cell lung cancer[J].Chest,2005,127(5):978-983.
9Heim MM,Eberhardt W,Seeber S,et al.Differential modulation of chemosensitivity to alkylating agents and platinum compounds by DNA repair modulators in human cancer cell lines[J].Cancer Res Clin Oncol,2000,126 (4):198-204.
10Boldrini L,Faviana P,Cisfredi S,et al.Identification of Fas(APO-1/CD95) and P53 gene multations in non-small cell lung cancer[J].Int Oncol,2002,20(1):155-159.
二级参考文献22
1曹治权.微量元素与中医药[M].中国中医药出版社,1996,2..
2Pennisi E. New tumor suppressor found-twice[ J]. Science, 1997,275 ( 3 ) : 1876-1878.
3Li J, Yen C, Liaw D, et al. PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer[ J]. Science, 1997,275 ( 8 ) : 1943-1947.
4Caims P,Okami K,Halachmi S,ct al. Frequent inactivation of PTEN/MMAC1 in primary prostate cancer[ J]. Cancer Res, 1997,57 (8) :4997-5000.
5MeMenamin ME, Soung P, Perera S, et al. Loss of PTEN expression in paraffin-embedded primary prostate cancer correlates with high Gleason score and advanced stage [ J ]. Cancer Res, 1999,59 (1) :4291-4296.
6Gulderg P, Straten PT, Binak A, et al. Disruption to the MMAC1/PTEN gene by deletion or mutation is a frequent event in malignant melanoma [ J ]. Cancer Res, 1997,57 ( 3 ) :3660-3663.
7Kohon T, Takahashi M, Manda R, ct al. Inactivation of the PTEN/MMAC1 gcnc in human lung cancers [ J ]. Genes Chromosomes Cancer, 1998,22 (2) : 152-156.
8Whang YE, Wu X, Suzuki H, et al. Inactivation of the tumor suppression PTEN/MMAC1 in advanced human prostate cancer through loss of expression [ J ]. Proc Nat1 Aead Sci USA, 1998,95 ( 12 ) :5246 -5250.
9West AK, Stallings R, Hildebrand CE, et al. Human metallothionein genes:structure of the functional locus at 16q13. Genomics, 1990, 8 (3): 513-518
10Hart BA, Voss GW, Vacek PM, et al. Metallothionein in human lung carcinoma. Cancer Lett, 1993, 75: 121-128
